5-amino-1,2,3,4-tetrahydropyrimidine-2,4-dione

• ChemBase编号: 3439
• 分子式: C4H5N3O2
• 平均质量: 127.1014
• 单一同位素质量: 127.03817642
• SMILES: Nc1c[nH]c(=O)[nH]c1=O
• Canonical SMILES: Nc1c[nH]c(=O)[nH]c1=O
• InChI: InChI=1S/C4H5N3O2/c5-2-1-6-4(9)7-3(2)8/h1H,5H2,(H2,6,7,8,9)
• InChIKey: BISHACNKZIBDFM-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-amino-1,2,3,4-tetrahydropyrimidine-2,4-dione
• IUPAC传统名: 5-amino-1,3-dihydropyrimidine-2,4-dione
• 别名: 5-氨基-2,4-二羟基嘧啶; 5-氨基-2,4-嘧啶二醇; 5-氨基尿嘧啶; 5-氨基脲嘧啶; 5-Amino-1h-Pyrimidine-2,4-Dione; 5-AMINO-2,4-DIHYDROXYPYRIMIDINE; 5-aminopyrimidine-2,4(1H,3H)-dione; 5-Aminouracil; 5-Amino-2,4-dihydroxypyrimidine; 5-Amino-2,4-pyrimidinediol; 5-AMINOURACIL

登记号

• CAS号: 932-52-5
• EC号: 213-252-3
• MDL号: MFCD00006025
• Beilstein号: 127250
• PubChem SID: 46507741; 24846367; 24888374; 160966878
• PubChem CID: 13611

理论计算性质

JChem

• Acid pKa: 8.573143
• 质子受体: 3
• 质子供体: 3
• LogD (pH = 5.5): -1.739659
• LogD (pH = 7.4): -1.7671776
• Log P: -1.7392963
• 摩尔折射率: 29.5942 cm^3
• 极化性: 10.840235 Å^3
• 极化表面积: 84.22 Å^2
• 可自由旋转的化学键: 0
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: -1.58
• LOG S: -1.05
• 溶解度: 1.13e+01 g/l

分子性质

理化性质

• 熔点: >300 °C(lit.); >300°C; >300°C

安全信息

• 保存条件: Room Temperature (15-30°C)
• RTECS编号: YQ8740000
• 欧盟危险性物质标志: X
• 德国WGK号: 3
• 危险公开号: 22
• 安全公开号: 36
• TSCA收录: 是
• GHS危险品标识: GHS06; GHS07
• GHS警示词: Warning
• GHS危险声明: H301; H302
• GHS警示性声明: P264-P270-P301+P310-P321-P405-P501A
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

产品相关信息

• 纯度: ≥98.0% (HPLC); 97%; 98%
• 级别: purum
• Empirical Formula (Hill Notation): C4H5N3O2

详细说明

MP Biomedicals - 02100648

Crystalline

MP Biomedicals - 05202456

MP Biomedicals Rare Chemical collection

DrugBank - DB03792

Drug information: experimental

Sigma Aldrich - 855286

包装
5, 25 g in poly bottle

参考文献

• Condensation with crotonaldehyde gives 2,4-dioxo-6-methylpyrido[3,2-d]pyrimidine: J. Chem. Soc. (C), 1745 (1967). An improved procedure has been used in synthesis of inhibitors of human thymidylate synthase: J. Med. Chem., 27, 1710 (1984), and of dihydrofolate reductases: J. Med. Chem., 39, 1836 (1996):
  
• Review of the use of uracils as starting materials in heterocyclic synthesis: Adv. Heterocycl. Chem., 55, 130 (1992).